Saturday, Aug 15 2020 | Time 10:22 Hrs(IST)
image
  • Kim congratulates Putin on 75th anniversary of Korea’s Liberation from Japan: KCNA report
  • Assam COVID cured tally crosses 50,000
  • California becomes first state in US with over 600,000 COVID-19 cases
  • UN chief calls for restraint, calm in Belarus
  • Mamata greets all on 74th Independence Day
  • Heightened security across Delhi on I-Day, COVID guidelines strictly enforced
  • Arunachal reports one more Covid-19 death
  • Arunachal Guv, CM , Speaker extend Independence Day greetings
  • PROGRESS WITH UNITY, EMPHASISES PM
  • IN NEXT 1000 DAYS, LAKSHADWEEP WILL ALSO BE CONNECTED TO SUBMARINE OPTICAL FIBRE CABLE: PM
  • PM FOCUSSES ON MILITARY MIGHT: ONE LAKH NCC CADETS IN BORDER AREAS
  • PM CALLS FOR UNITY IN SOUTH ASIA
  • PROJECT DOLPHIN TO BE LAUNCHED FOR CONSERVATION OF DOLPHINS: PM
  • Aatmanirbhar Bharat will be realised: PM Modi
World


Oxford's Covid vaccine starts trail in S Africa

Oxford's Covid vaccine starts trail in S Africa

Rio De Janeiro, Jul 2 (UNI) Researchers in South Africa and Brazil have initiated clinical trials to assess a Covid-19 vaccine candidate, ChAdOx1 nCoV-19 (AZD1222), developed by the University of Oxford and licensed to AstraZeneca.

Professor Sarah Gilbert from Nuffield Department of Medicine, Oxford University states that "We have removed some of the adenovirus genes so that when we use it as a vaccine, the adenovirus can't spread through the body. That makes it very safe, even in people with a weak immune system. But because it is still a live virus, it is good at inducing a strong immune response after vaccination"

"We started with an adenovirus, which was isolated from a chimpanzee and doesn't circulate in human populations, so there is no prior immunity to it. Then we add a gene to encode one of the proteins from the pathogen that we want to vaccinate against -- for SARS-CoV-2 we use the spike protein, which covers the surface of the coronavirus," added Gilbert.

According to a report published on Clinical trail Arena the University of Witwatersrand in South Africa is working with the University of Oxford and the Oxford Vaccine Group to evaluate the vaccine candidate. This marks South Africa’s first trial of a vaccine against Covid-19.

UNI XC PR JTS 1337

More News
Iran's Envoy ask US to not try Imposing any UNSC sanctions

Iran's Envoy ask US to not try Imposing any UNSC sanctions

15 Aug 2020 | 7:34 AM

United Nation, Aug 15 (UNI) Iran’s Ambassador to the United Nations Majid Takht Ravanchi on friday said 'The return of any UN Security Council sanctions on Iran will be met severely as the Islamic Republic’s options are not limited, and the United States will bear the full responsibility' .

see more..
Turkey mulls suspending ties with UAE, withdrawing ambassador

Turkey mulls suspending ties with UAE, withdrawing ambassador

14 Aug 2020 | 9:13 PM

Ankara, Aug 14 (UNI) Turkey’s president Recep Tayyip Erdogan indicated on Friday that his government could downgrade its ties with the United Arab Emirates (UAE) over the latter's decision to normalise its relations with Israel.

see more..

COVID-19: Nepal reports 594 new cases

14 Aug 2020 | 7:14 PM

Kathmandu, Aug 14 (UNI) The Novel Coronavirus count in Nepal reached 25,551 on Friday, after 594 new cases were recorded during the past 24 hours, the country's Health Ministry confirmed.

see more..
Landslide in Nepal kills 5, over 30 people missing

Landslide in Nepal kills 5, over 30 people missing

14 Aug 2020 | 4:55 PM

Kathmandu, Aug 14 (UNI) At least five people died and over 30 went missing in a landslide at Jugal Rural Municipality in Sindhupalchowk district in central Nepal on Friday, a local government official and police said.

see more..
nCoV: 34 more fatalities, 2,766 new infections in Bangladesh

nCoV: 34 more fatalities, 2,766 new infections in Bangladesh

14 Aug 2020 | 4:32 PM

Dhaka, Aug 14 (UNI) The deaths related to the novel coronavirus reached 3,591 in Bangladesh on Friday as the
country recorded 34 more fatalities from the virus in the past 24 hours.

see more..
image